StockNews.com upgraded shares of GlycoMimetics (NASDAQ:GLYC – Free Report) from a sell rating to a hold rating in a research report released on Thursday morning. Separately, Capital One Financial assumed coverage on GlycoMimetics in a research report on Friday, December 22nd. They set an overweight rating and a $12.00 target price for the company. Check […]
Capital One Financial initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a report released on Friday morning, Marketbeat reports. The firm issued an overweight rating and a $12.00 price objective on the biotechnology company’s stock. Separately, StockNews.com cut GlycoMimetics from a hold rating to a sell rating in a report on Monday, […]
GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.36 and traded as high as $1.53. GlycoMimetics shares last traded at $1.53, with a volume of 79,729 shares. Analyst Ratings Changes Several research analysts recently weighed in […]
By Ben Glickman Shares of GlycoMimetics rose Tuesday after its chief medical officer bought over $90,000 worth of stock. The stock was up 12% to $1.44 in.